Haldol and Haloperidol: How This First-Generation Antipsychotic Is Used in Clinical Practice

Haloperidol, marketed under the brand name Haldol, is a first-generation antipsychotic belonging to the butyrophenone class. Introduced in the late 1950s, it became one of the most widely used antipsychotic agents before the development of second-generation atypical antipsychotics and remains clinically relevant today due to its efficacy in acute settings, its available intravenous and intramuscular formulations, and its well-understood pharmacological profile. Haloperidol works primarily by blocking dopamine D2 receptors in the mesolimbic pathway, reducing dopaminergic activity that is thought to contribute to positive psychotic symptoms including hallucinations, delusions, and disorganized thinking. This D2 blockade is strong and selective, which explains both its antipsychotic efficacy and its well-characterized side effect profile. FDA-approved indications for haloperidol include schizophrenia, Tourette syndrome, and behavioral agitation in children and adults. Off-label uses supported by clinical evidence include management of acute delirium in hospitalized patients, agitation in emergency and intensive care settings, nausea refractory to first-line antiemetics, and behavioral disturbances associated with dementia. Haloperidol's D2 potency makes extrapyramidal side effects one of its most significant clinical concerns. These include akathisia, a distressing sense of restlessness and inability to remain still; dystonia, involuntary muscle contractions that can affect posture and movement; parkinsonism, characterized by tremor, rigidity, and bradykinesia; and tardive dyskinesia, a potentially irreversible movement disorder associated with prolonged use. Dose minimization and regular monitoring for movement disorder emergence are standard components of ongoing management. The long-acting injectable haloperidol decanoate formulation is used for patients with schizophrenia who have difficulty maintaining consistent oral adherence. Monthly or every four-week injections allow stable drug levels without reliance on daily oral dosing. QTc prolongation is a cardiac concern with haloperidol at higher intravenous doses, and electrocardiogram monitoring is part of the safety protocol when IV haloperidol is used in hospital settings. Haloperidol is listed among the Beers Criteria medications to avoid or use with caution in older adults due to elevated extrapyramidal and cognitive risks in that population. For patients and families seeking to understand haloperidol's clinical role, reviewing information about haldol-haloperidol for psychosis and agitation management provides a useful clinical overview. For context on how haloperidol compares to second-generation antipsychotics in the broader treatment category, antipsychotic medication category guides and patient resources offers comparative information.